 |
 Video: What is a Stock Split?
|
|
|
| Vor Biopharma is a cell therapy company. Co.'s primary focus is on patients suffering from acute myeloid leukemia (AML). Co. develops treatments for patients suffering from hematological malignancies. Co. is developing its primary eHSC product candidate, VOR33, which it has potential to transform the treatment for AML and other blood cancers. CD33 is a clinically validated target for AML. Co. has initiated VBP101, a Phase 1/2a clinical trial in patients with CD33-positive AML who are at high risk of relapse. Co. is also developing its Treatment System comprising the VOR33-CLL1 multiplex-edited eHSC therapy and the VCAR33-CLL1 multi-specific CAR-T therapy. According to our Vor Biopharma stock split history records, Vor Biopharma has had 0 splits. | |
|
Vor Biopharma (VOR) has 0 splits in our Vor Biopharma stock split history database.
Looking at the Vor Biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vor Biopharma shares, starting with a $10,000 purchase of VOR, presented on a split-history-adjusted basis factoring in the complete Vor Biopharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/08/2021 |
|
| End date: |
04/19/2024 |
|
| Start price/share: |
$42.83 |
|
| End price/share: |
$1.71 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-96.01% |
|
| Average Annual Total Return: |
-63.54% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$399.41 |
|
| Years: |
3.19 |
|
|
|
|
|
